Surgery Doctors in Carmel, IN Accepting Medicare

25 Surgery doctors found. Showing 21 - 25

Kirpal Singh, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 12188b N Meridian St Ste 250, Carmel, IN 46032 Phone: 317-705-4825    Fax: 317-705-4826

William R Finkelmeier, MD Surgery - Vascular Surgery Medicare: Accepting Medicare Assignments Practice Location: 13450 N Meridian St Ste 160, Carmel, IN 46032 Phone: 317-582-7676

Mrs. Margaret Murphy Inman, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 13430 N Meridian St, Suite 275, Carmel, IN 46032 Phone: 317-582-8810    Fax: 317-582-8863

Kandice K Ludwig, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 11725 N Illinois Street, Suite 545, Carmel, IN 46032 Phone: 317-688-3220    Fax: 317-688-5150

Justin Wayne Hart, D.O. Surgery Medicare: Medicare Enrolled Practice Location: 13450 N Meridian St Ste 145, Carmel, IN 46032 Phone: 317-338-8788

News Archive

Aphios awarded US patent for compositions, methods for treating diseases involving 5-α reductase enzyme

Aphios® Corporation today announced that it was awarded United States Patent No. 7,744,935 B2 for "Compositions and Methods for Inhibiting 5-α Reductase," granted June 29, 2010. This invention is related to compositions and methods for treating diseases involving the 5-alpha (α) reductase enzyme.

Scientists aim to develop latest biosensors for personalized medicine, drug development

Scientists at the Leibniz Institute for Molecular Pharmacology in Berlin-Buch and the California Institute of Technology in Pasadena cooperate in the future for the development of the latest biosensors for usage related to personalized medicine and drug development.

New study describes therapeutic approach to halt cancer progression

A new study describes a therapeutic approach to halting cancer progression by exploiting a previously unrecognized "addiction" of leukemia cells to specific signaling molecules. The research, published by Cell Press online on April 16th in the journal Cancer Cell, identifies non-classical oncogenes critical for tumor development and survival, and describes a potentially less toxic strategy that selectively targets these molecules.

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

HealthCore, Inc., the outcomes research subsidiary of Anthem, Inc. and Novo Nordisk Inc., which manufacturers the once weekly GLP-1 receptor agonist Ozempic (semaglutide), are working together to launch the first of its kind pragmatic study to understand the benefits of semaglutide as compared with all other available diabetes drugs in a real-world pragmatic clinical trial for Type 2 diabetes - one of the nation's fastest growing chronic diseases.

Potential new strategies for treating obsessive compulsive disorder

Using genetic engineering, researchers have created an obsessive-compulsive disorder (OCD) - like set of behaviors in mice and reversed them with antidepressants and genetic targeting of a key brain circuit.

Read more Medical News

› Verified 2 days ago

• 1
• 2(current)